HomeComparePFE vs CTSH

PFE vs CTSH: Dividend Comparison 2026

PFE yields 6.20% · CTSH yields 2.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTSH wins by $17.9K in total portfolio value
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
CTSH
CTSH
● Live price
2.06%
Share price
$61.06
Annual div
$1.26
5Y div CAGR
42.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.0K
Annual income
$18,542.84
Full CTSH calculator →

Portfolio growth — PFE vs CTSH

📍 CTSH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFECTSH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + CTSH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
CTSH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
CTSH
Annual income on $10K today (after 15% tax)
$175.40/yr
After 10yr DRIP, annual income (after tax)
$15,761.41/yr
At 15% tax rate, PFE beats the other by $7,367.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + CTSH for your $10,000?

PFE: 50%CTSH: 50%
100% CTSH50/50100% PFE
Portfolio after 10yr
$60.1K
Annual income
$22,876.69/yr
Blended yield
38.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CTSH right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
CTSH
Analyst Ratings
22
Buy
24
Hold
5
Sell
Consensus: Hold
Price Target
$91.00
+49.0% upside vs current
Range: $71.00 — $107.00
Altman Z
6.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
CTSH buys
0
No recent congressional trades found for PFE or CTSH in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFECTSH
Forward yield6.20%2.06%
Annual dividend / share$1.72$1.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%42.7%
Portfolio after 10y$51.1K$69.0K
Annual income after 10y$27,210.54$18,542.84
Total dividends collected$60.1K$44.3K
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusHoldHold
Analyst price target$27.50$91.00

Year-by-year: PFE vs CTSH ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrCTSH PortfolioCTSH Income/yrGap
1← crossover$9,161$701.38$10,994$294.47$1.8KCTSH
2$8,610$859.79$12,196$431.77$3.6KCTSH
3$8,366$1,081.25$13,688$638.75$5.3KCTSH
4$8,483$1,405.66$15,603$956.11$7.1KCTSH
5$9,084$1,907.24$18,148$1,453.43$9.1KCTSH
6$10,418$2,732.78$21,673$2,254.62$11.3KCTSH
7$13,007$4,193.56$26,781$3,590.89$13.8KCTSH
8$18,010$7,005.87$34,574$5,917.65$16.6KCTSH
9$28,216$12,979.89$47,182$10,188.34$19.0KCTSH
10$51,081$27,210.54$69,028$18,542.84$17.9KCTSH

PFE vs CTSH: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

CTSHTechnology

Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. It operates through four segments: Financial Services; Healthcare; Products and Resources; and Communications, Media and Technology. The company offers customer experience enhancement, robotic process automation, analytics, and AI services in areas, such as digital lending, fraud detection, and next generation payments; the shift towards consumerism, outcome-based contracting, digital health, delivering integrated seamless, omni-channel, and patient-centered experience; and services that drive operational improvements in areas, such as clinical development, pharmacovigilance, and manufacturing, as well as claims processing, enrollment, membership, and billing to healthcare providers and payers, and life sciences companies, including pharmaceutical, biotech, and medical device companies. It also provides solution to manufacturers, retailers and travel and hospitality companies, as well as companies providing logistics, energy and utility services; and digital content, the creation of personalized user experience, and acceleration of digital engineering services to information, media and entertainment, and communications and technology companies. The company was founded in 1994 and is headquartered in Teaneck, New Jersey.

Full CTSH Calculator →
📬

Get this PFE vs CTSH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.